LexaGene (CVE:LXG) and Akumin (TSE:AKU) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk.
Analyst Ratings
This is a summary of recent ratings and price targets for LexaGene and Akumin, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
LexaGene | 0 | 0 | 0 | 0 | N/A |
Akumin | 0 | 1 | 1 | 0 | 2.50 |
Akumin has a consensus target price of C$4.25, suggesting a potential upside of 8.97%. Given Akumin's higher probable upside, analysts clearly believe Akumin is more favorable than LexaGene.
Profitability
This table compares LexaGene and Akumin's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
LexaGene | N/A | N/A | N/A |
Akumin | N/A | N/A | N/A |
Valuation & Earnings
This table compares LexaGene and Akumin's gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
LexaGene | N/A | N/A | N/A | C($0.12) | -5.63 |
Akumin | C$246.08 million | 1.10 | C$-25,194,260.00 | C($0.36) | -10.71 |
LexaGene has higher earnings, but lower revenue than Akumin. Akumin is trading at a lower price-to-earnings ratio than LexaGene, indicating that it is currently the more affordable of the two stocks.
Summary
Akumin beats LexaGene on 3 of the 5 factors compared between the two stocks.